Stay updated on Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial
Sign up to get notified when there's something new on the Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial page.

Latest updates to the Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial page
- CheckyesterdayChange DetectedFooter revision updated from v3.3.3 to v3.3.4 with no other content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded a Locations section with Kentucky as a study site. Removed the Kentucky Locations entry and the HHS Vulnerability Disclosure link; revision updated to v3.3.3.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0. This is a metadata update and does not alter the study details.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved the government funding/status notice related to NIH operations. The study details, eligibility criteria, and contact information on the page remain unchanged.SummaryDifference0.4%

- Check73 days agoChange DetectedThe update appears to adjust page layout and formatting without altering key study details such as eligibility, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check102 days agoChange Detected- Added a government funding lapse notice with operating status guidance for NIH Clinical Center and links to cc.nih.gov and opm.gov. - Updated version to v3.2.0. - Removed the previous v3.1.0 version tag.SummaryDifference5%

Stay in the know with updates to Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neoadjuvant Immunotherapy Combination in Stage III Melanoma Clinical Trial page.